Phio Pharmaceuticals Highlights siRNA Oncology Program at DealFlow
KING OF PRUSSIA, PENNSYLVANIA | January 26, 2026 — Phio Pharmaceuticals has announced its participation in the Third Annual...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
KING OF PRUSSIA, PENNSYLVANIA | January 26, 2026 — Phio Pharmaceuticals has announced its participation in the Third Annual...
BOSTON, Massachusetts — January 12, 2026 — Junevity has announced the publication of its first peer-reviewed scientific study demonstrating...
King of Prussia, Pennsylvania | December 23, 2025 — Phio Pharmaceuticals Corp. announced a significant advancement in its drug...
